CVEvulnerability

CVE-2026-42933

10.0 CRITICAL Published 2026-07-23 Modified 2026-10-24 Official page ↗
Status
Deferred
Published
2026-07-23
Last modified
2026-10-24
Assigner
[email protected]
CVSS 4.0 ([email protected])
10.0 CRITICAL — CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:H/SI:H/SA:H/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
CVSS 3.1 ([email protected])
10.0 CRITICAL — CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:C/C:H/I:H/A:H
Weaknesses
CWE-441

Description

Pronetiqs IntraVUE versions 3.2.1a14 and prior have an unintended proxy or intermediary vulnerability which could allow an attacker to use an active proxy, which would bypass OT segmentation.

Related

Weakness · CWE (1)

  • CWE-441 Unintended Proxy or Intermediary weakness

References